Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07628530

Reference Equations and Normative Data for Isometric Quadriceps and Handgrip Muscles STrength in Southern European Populations - RESTart: a Multicentre Study

This observational study aims to learn about peripheral muscle strength in healthy adults and people with chronic respiratory diseases. The study aims to develop reference data for quadriceps muscle strength and handgrip in adults living in Southern Europe and to assess whether these reference data can be used in people with chronic respiratory diseases.

The main questions it aims to answer are:

* What are the normal values for quadriceps and handgrip muscle strength in healthy adults aged 18-89 years living in Spain, Portugal and Italy? * Can the reference values developed in healthy adults be applied to people with chronic respiratory diseases?

Participants will attend one study visit. During this visit, researchers will:

* Measure quadriceps muscle strength and handgrip. * Collect information about age, sex, height, weight and other health characteristics. * Perform simple functional tests related to mobility and physical performance. * Ask participants to complete questionnaires about symptoms, physical activity and health-related quality of life.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

The RESTart study (Reference equations and normative data for isometric quadriceps and handgrip STrength in Southern European populations) is a multicentre observational cross-sectional study conducted in Spain, Portugal and Italy.

Peripheral muscle dysfunction, particularly reduced quadriceps muscle strength and handgrip, is common in people with chronic respiratory diseases and is associated with impaired physical function, hospitalisation and mortality. Accurate interpretation of muscle strength measurements requires population-specific reference equations and normative values. However, currently available reference data may not adequately represent Southern European populations.

The primary objective of the study is to develop reference equations and normative values for isometric quadriceps muscle strength and handgrip in healthy adults aged 18-89 years. A secondary objective is to validate/assess clinical application of these reference data in people with chronic respiratory diseases, including chronic obstructive pulmonary disease, interstitial lung disease, asthma, bronchiectasis and cystic fibrosis.

Healthy participants will be recruited from community settings using proportional stratification according to age, sex and country. Participants with chronic respiratory diseases will be recruited from collaborating clinical centres.

Primary outcomes are isometric quadriceps muscle strength and handgrip assessed using standardised dynamometry protocols. Secondary outcomes include functional capacity, mobility and balance, symptoms, physical activity, health-related quality of life, and anthropometric variables; lung function and laboratory parameters only when available from medical records.

The study is expected to provide robust reference equations and normative values for Southern European populations, supporting improved identification and monitoring of peripheral muscle dysfunction in both clinical practice and research.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Healthy adults cohort

Inclusion criteria

  • Age between 18-89 years.
  • Spanish, Portuguese or Italian, or permanently resident in one of those countries for at least five years.
  • Be community-dwelling (i.e., not hospitalised or institutionalised).
  • Be functionally independent and capable of performing study assessments without assistance or limiting pain.
  • Be able to follow verbal instructions in the local language (Spanish, Portuguese or Italian, as appropriate).
  • Provide written informed consent.

Exclusion criteria

  • Acute or chronic musculoskeletal conditions affecting strength: recent fractures, severe osteoarthrosis, ligament injury, acute tendinitis in hands/knee areas, among others.
  • Recent surgery (e.g., within the past six months) in upper or lower limbs.
  • Neuromuscular disorders: Parkinson, multiple sclerosis, stroke, peripheral neuropathies, among others.
  • Non-communicable diseases affecting strength or functional status: active cancer, any unstable heart diseases; any CRD; active rheumatological diseases, obesity (BMI≥30kg/m2), uncontrolled metabolic diseases, among others (not included: controlled dyslipidaemia or arterial hypertension).
  • Cognitive impairments (e.g., dementia) or psychiatric disorders impairing following instructions.
  • Aid devices for walking or compromised functional mobility.
  • Moderate-to-severe pain during the assessment (VAS ≥4).
  • Systemic corticosteroids use for over one week in the previous six months (i.e., risk of muscle atrophy in type II fibres; or steroid myopathy).
  • Muscle relaxants use during the previous week (i.e., risk of not full muscle activation).
  • Pregnancy and postpartum (i.e., potential physiological changes which may alter muscle strength).
  • Current smoking.

Chronic respiratory disease cohort

Inclusion criteria

  • Aged 18-89 years.
  • Clinical diagnosis of a chronic respiratory disease (e.g., COPD, interstitial lung disease, asthma, bronchiectasis, cystic fibrosis), confirmed by spirometry or clinical records.
  • Clinically stable (no exacerbation within the past four weeks).
  • Capacity to provide informed consent and complete study procedures.

Exclusion criteria

  • Coexisting conditions which meet the exclusion criteria defined for healthy participants, apart from chronic respiratory diseases.
  • Current requirement for hospitalisation or acute medical management.
  • Severe functional limitation preventing completion of assessments.

Treatment and study plan

Primary outcomes

  1. Isometric quadriceps muscle strength

    Time frame: Day 1

    Quadricpes maximum voluntary contraction measured using a handheld dynamometer according to the standardised RESTart protocol. Strength will be recorded as the highest value obtained during the assessment and expressed in kilograms-force (kgf).

  2. Handgrip

    Time frame: Day 1

    Handgrip mMaximum voluntary contraction measured using a hydraulic handgrip dynamometer according to standardised assessment procedures. Strength will be recorded as the highest value obtained during the assessment and expressed in kilograms-force (kgf).

Secondary outcomes

  1. Five-repetition sit-to-stand test

    Time frame: Day 1

    Functional capacity assessed by the time required to complete five sit-to-stand repetitions according to standardised procedures. Results will be expressed in seconds. Lower values indicate better lower-limb functional capacity.

  2. One-minute sit-to-stand test

    Time frame: Day 1

    Functional capacity assessed as the number of sit-to-stand repetitions completed in one minute according to standardised procedures. Higher values indicate better functional exercise capacity.

  3. Timed Up and Go test

    Time frame: Day 1

    Mobility and dynamic balance assessed using the Timed Up and Go test. Results will be expressed in seconds. Lower values indicate better mobility and dynamic balance.

  4. Modified Medical Research Council dyspnoea scale

    Time frame: Day 1

    Dyspnoea severity assessed using the modified Medical Research Council dyspnoea scale. Scores range from 0 to 4, with higher scores indicating greater breathlessness.

  5. Modified Borg dyspnoea scale

    Time frame: Day 1

    Perceived breathlessness assessed using the modified Borg dyspnoea scale. Scores range from 0 to 10, with higher scores indicating greater breathlessness.

  6. Dyspnoea-12

    Time frame: Day 1

    Dyspnoea assessed using the Dyspnoea-12 questionnaire. The total score ranges from 0 to 36, with higher scores indicating more severe breathlessness.

  7. Functional Assessment of Chronic Illness Therapy-Fatigue

    Time frame: Day 1

    Fatigue assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue questionnaire. Scores range from 0 to 52, with higher scores indicating less fatigue.

  8. EuroQol 5-Dimension 5-Level

    Time frame: Day 1

    Health-related quality of life assessed using the EuroQol 5-Dimension 5-Level (EQ-5D) questionnaire. The index score will be calculated according to the appropriate national value set. Higher scores indicate better health status. Self-rated health assessed using the EQ-5D Visual Analogue Scale. Scores range from 0 to 100, with higher scores indicating better perceived health.

  9. St George's Respiratory Questionnaire

    Time frame: Day 1

    Respiratory-specific health-related quality of life assessed using the St George's Respiratory Questionnaire. Scores range from 0 to 100, with higher scores indicating worse respiratory health-related quality of life.

  10. International Physical Activity Questionnaire-short form

    Time frame: Day 1

    Physical activity assessed using the International Physical Activity Questionnaire-short form. Results will be expressed as minutes per week spent in vigorous/moderate/total physical activity, time per week spent walking and hours per day spent in sedentary behaviour (sitting).

  11. Mini Nutritional Assessment-short form

    Time frame: Day 1

    Nutritional status assessed using the Mini Nutritional Assessment-short form. Scores range from 0 to 14, with higher scores indicating better nutritional status.

Other outcomes

  1. Age

    Time frame: Day 1

    Participant age recorded in completed years.

  2. Weight

    Time frame: Day 1

    Participant weight recorded in kilograms.

  3. Height

    Time frame: Day 1

    Participant height recorded in metres.

  4. Body mass index

    Time frame: Day 1

    Body mass index calculated as weight divided by height squared.

  5. Sex

    Time frame: Day 1

    Participant biological sex recorded as female or male.

  6. Forced expiratory volume in one second percentage predicted (FEV1%pred)

    Time frame: Day 1

    Lung function measured by spirometry when available from medical records.

  7. Forced vital capacity percentage predicted (FVC%pred)

    Time frame: Day 1

    Lung function measured by spirometry when available from medical records.

  8. Systemic inflammation markers

    Time frame: Day 1

    CRP, IL-6, eosinophils, fibrinogen, neutrophil elastase, ESR, KL-6, SP-D, FeNO, IgE, calprotectin, if available, from medical records.

  9. Charlson Comorbidity Index

    Time frame: Day 1

    Comorbidity burden assessed using the Charlson Comorbidity Index. Higher scores indicate greater comorbidity burden.

  10. Anatomical Therapeutic Chemical (ATC) Classification System

    Time frame: Day 1

    Current medication use classified according to the Anatomical Therapeutic Chemical (ATC) Classification System.

  11. Smoking Exposure (pack-year index)

    Time frame: Day 1

    Lifetime smoking exposure quantified using the pack-year index, calculated from self-reported smoking history.

  12. Alcohol Use Disorders Identification Test-Consumption

    Time frame: Day 1

    Alcohol consumption assessed using the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C). Higher scores indicate greater alcohol consumption and increased risk of hazardous drinking.

Study contacts

Contact information is provided by the study sponsor or research team.

María Torres-Lacomba, PT, Ph.D.

CONTACT

[email protected]

+34 918 85 48 28

Nicola S. Diciolla, PT, Ph.D.

CONTACT

[email protected]

+34 918 85 48 28

Sponsors and collaborators

Lead sponsor

University of Alcala

Other

Registry information

Acronym: RESTart

Important dates

Study start
2026
Primary completion
2029
Study completion
2030
First posted
Jun 5, 2026
Registry last updated
Jun 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.